November 7, 2008
Bio-Bridge Science Announces the Appointment of Mitchell Kronenberg, Ph.D. To Its Scientific Advisory Board
Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company engaged in the commercial development of vaccines for the prevention and treatment of human infectious diseases, announced the appointment of Dr. Mitchell Kronenberg to the Scientific Advisory Board of the Company. Dr. Kronenberg is an internationally recognized leading expert on NKT cells and mucosal immunology. He has over 230 highly cited publications, is currently on the Finance Committee of the American Association of Immunologists and serves as a Deputy Editor for the Journal of Immunology. Dr. Kronenberg was named a Roy and Robert Kroc Distinguished Visiting Professor of Immunology and Medicine by the University of California, Davis in 2000, and was a Borroughs Wellcome Fund Visiting Professor at Harvard University in 2002.
Dr. Liang Qiao, Chairman and CEO of Bio-Bridge Science, commented, "We are very pleased to work with Dr. Kronenberg. His expertise and experience in immunology is widely respected and we look forward to receiving his valuable advice and recommendations."
Dr. Kronenberg joins Dr. Katherine Knight, Chairperson and Professor of Microbiology and Immunology at Loyola University Chicago and past President of the American Association of Immunologists, on the Scientific Advisory Board of Bio-Bridge Science.
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Please refer to the Company's SEC filings for additional information.